UroGen Pharma (NASDAQ:URGN) closed Friday up ~43%, a week before the U.S. FDA is set to act on its NDA for UGN-102 (mitomycin)
https://seekingalpha.com/news/4456345-urogen-closes-up-43-ahead-of-fda-decision-on-bladder-cancer-candidate
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.